GSDMD and mastitis: PANoptosis activation is an effective therapeutic target during mastitis progression, and Gasdermin D activation is key factor contributing to blood milk barrier damage during mastitis, while cyanidin 3‐O‐galactoside can inhibit these targets to exert a protective effect.